Navidea Biopharmaceuticals, Inc. Bankruptcy Case

Case filing & court posture: Navidea Biopharmaceuticals, Inc. filed chapter 11 on October 1, 2025 in Delaware (Case No. 25-11779). Dkt. 1 Judge J. Kate Stickles presides. The case was filed under Subchapter V.
Liquidity & financing path: The debtor obtained a $1.6 million DIP facility from majority shareholder John Kimball Scott, Jr. at 10% interest (PIK). Dkt. 12 Interim DIP order entered October 9, 2025 Dkt. 32, with final order approved November 7, 2025. Dkt. 122
Restructuring outcome: The debtor pursued a sale process for substantially all assets. Dkt. 146 Bid procedures were approved December 11, 2025 Dkt. 166, and an auction was held January 22, 2026.
Sale approval & terms: Cardinal Health 414, LLC was selected as the successful bidder Dkt. 210 with a purchase price of $11,950,000 cash plus assumption of certain liabilities. The sale was approved January 30, 2026.

Case filing & court posture: Navidea Biopharmaceuticals, Inc. filed chapter 11 on October 1, 2025 in Delaware (Case No. 25-11779). Dkt. 1 Judge J. Kate Stickles presides. The case was filed under Subchapter V.
Liquidity & financing path: The debtor obtained a $1.6 million DIP facility from majority shareholder John Kimball Scott, Jr. at 10% interest (PIK). Dkt. 12 Interim DIP order entered October 9, 2025 Dkt. 32, with final order approved November 7, 2025. Dkt. 122
Restructuring outcome: The debtor pursued a sale process for substantially all assets. Dkt. 146 Bid procedures were approved December 11, 2025 Dkt. 166, and an auction was held January 22, 2026.
Sale approval & terms: Cardinal Health 414, LLC was selected as the successful bidder Dkt. 210 with a purchase price of $11,950,000 cash plus assumption of certain liabilities. The sale was approved January 30, 2026.

Navidea Biopharmaceuticals, Inc.